Highest-materiality recent filing
Harrow Q1 revenue $44.2M, net loss $27.6M; VEVYE market share reaches 14%
Revenue of $44.2M, down 8% YoY, including ~$8M non-recurring gross-to-net adjustment related to new VEVYE commercial coverage.
Q4 revenue $89.1M record (+33% YoY); full-year 2025 revenue $272.3M (+36%).
Reaffirmed FY2025 revenue guidance of $270-280 million; full-year results expected in early March.
Harrow Q3 revenue $71.6M (+45% YoY), net income $1.0M; VEVYE revenue $22.6M (+22% QoQ)
Total revenue $71.6M (+45% YoY); GAAP net income $1.0M vs loss $4.2M YoY; Adj. EBITDA $22.7M vs $8.8M
ImprimisRx (Harrow subsidiary) appoints Frank Mullery as CEO; prior CEO John Saharek transitions out
John Saharek ceased as President/CEO of ImprimisRx effective Oct 6, 2025; transitions to non-officer role with no new compensation.
Harrow to acquire Melt Pharmaceuticals for $0.50/share; already owns 45%
Harrow will pay $0.50 per share of Melt Common Stock for the remaining ~55% it does not already own.
Harrow signs definitive deal to acquire Melt Pharma for initial $4.3M plus milestones up to ~$352.5M
Initial cash payment of ~$4.3M for remaining 55% equity; contingent $87.2M upon FDA approval of MELT-300.
Harrow issues $250M 8.625% senior notes due 2030; redeems 2026 notes
Issued $250M aggregate principal of 8.625% senior notes due 2030; net proceeds ~$244M.
$250M 8.625% senior unsecured notes due 2030 priced at par; interest semi-annual starting March 15, 2026.
Launched $250M offering of senior unsecured notes due 2030 to refinance existing debt, including redemption of 2026 Notes (8.625%, $75M) and 2027 Notes (11.875%, $40.25M).
Harrow Q2 revenue $63.7M (+30% YoY); net income $5M; VEVYE on track for >$100M; adds Samsung Bioepis
Total revenues $63.7M, up 30% YoY; GAAP net income $5.0M vs loss of $6.5M; Adj EBITDA $17.0M (up from $8.8M).
Harrow secures exclusive U.S. rights to two ophthalmology biosimilars from Samsung Bioepis
Gains exclusive U.S. commercial rights to BYOOVIZ (ranibizumab-nuna) and OPUVIZ (aflibercept-yszy), FDA-approved biosimilars of Lucentis and Eylea.
Harrow licenses exclusive U.S. rights to BYQLOVI ophthalmic steroid from Formosa
Upfront payment of $500,000 at first commercial sale; additional milestone payments and royalties on gross profits.
Revenues $47.8M, up 38% YoY; GAAP net loss $(17.8)M; adjusted EBITDA $(2.0)M.
Harrow Q4 revenue $66.8M (+84% YoY), net income $6.8M; FY2025 guidance >$280M
Q4 revenue $66.8M (+84% YoY); FY2024 revenue $199.6M (+53% YoY).
Harrow reports preliminary Q4 revenue $65-67M, FY ~$199M; 2025 guidance >$280M
Preliminary Q4 2024 revenue $65-67M; full-year revenue $198-200M, both records.
Harrow Q3 revenue up 44% to $49.3M; reaffirms FY2024 guidance above $180M
GAAP net loss of $4.2M; Adjusted EBITDA $8.8M; core gross margin improved to 80%.
Harrow draws $30M under Oaktree loan for Novartis Triescence milestone; amends credit terms
Drew $30M on Oct 25, 2024, under Oaktree Loan to partially fund $37M milestone to Novartis for Triescence commercial availability.
Harrow Q2 2024 record revenue $48.9M (+46% YoY); adj EBITDA $8.8M; guides FY rev >$180M
Record Q2 revenue $48.9M, up 46% YoY and 42% sequentially; GAAP net loss $(6.5)M.
Harrow Q1 revenue up 33% to $34.6M; net loss widens; FY2024 guidance at least $180M
Q1 revenue $34.6M (+33% YoY); GAAP net loss $(13.6M) vs $(6.6M) prior year; adj. EBITDA $0.2M vs $5.3M.
CMS approved increase of Medically Unlikely Edit (MUE) for IHEEZO J-Code J2403 from 1 to 2 units.
Harrow gets CMS confirmation that IHEEZO is separately payable in physician office setting
CMS confirmed IHEEZO's J-Code 2403 will be included in April 2024 quarterly ASP drug pricing file.
Harrow full-year 2023 revenue $130.2M (+47% YoY), GAAP net loss widens to $24.4M; adj EBITDA $28.1M
FY2023 revenue $130.2M, up 47% YoY; GAAP net loss $24.4M (vs $14.1M loss in 2022).
Harrow terminates $18.4M Melt loan, takes ~47% equity stake; appoints Saharek division president
Terminated Loan Agreement with Melt; received 2.26M Series B-1 and 74k Series B preferred shares in full settlement of ~$18.4M outstanding.
Harrow Q3 rev up 50% to $34.3M, cuts FY2023 outlook, targets >$180M in 2024
Record Q3 rev $34.3M (+50% YoY); GAAP net loss $4.4M; Adjusted EBITDA $9.2M (+270% YoY).
Record revenues of $33.5M, up 44% YoY; GAAP net loss of $4.2M.
Harrow Health raises $69M in stock offering to fund acquisition
Priced public offering of 3,380,282 shares at $17.75/share, initially raising $60M; underwriters later exercised full option for 507,042 additional shares.
Harrow acquires VEVYE and Santen ophthalmic rights; Q2 revenue guidance >$31M
Acquired U.S./Canadian rights to VEVYE (cyclosporine 0.1%) from Novaliq; $8M upfront + low double-digit royalties.
Harrow reports record Q1 revenue of $26.1M, up 18% YoY; reaffirms 2023 guidance
Record Q1 2023 revenue $26.1M, up 18% YoY vs $22.1M and 28% sequentially (from $20.3M).
On January 17, 2025, Marty A. Makary informed the Board of Directors (the “Board”) of Harrow, Inc. (the “Company”) that he is resigning as a member of the Company’s Board, with such resignation to be effective as of 11:59 p.m. ET on January 19, 2025.
On January 26, 2024 (the “Effective Date”), the board of directors (the “Board”) of Harrow, Inc. (the “Company”), following the recommendation of the Nomination and Corporate Governance Committee of the Board, expanded the size of the Board from four members to six and elected Adrienne L. Graves, Ph.D. and Lauren P. Silvernail to serve as members of the Board, effective immediately.
On January 26, 2024 (the “Effective Date”), the board of directors (the “Board”) of Harrow, Inc. (the “Company”), following the recommendation of the Nomination and Corporate Governance Committee of the Board, expanded the size of the Board from four members to six and elected Adrienne L. Graves, Ph.D. and Lauren P. Silvernail to serve as members of the Board, effective immediately.
Effective January 2, 2024, Harrow, Inc. (the “Company”) appointed John P. Saharek as the President and Chief Executive Officer of the Company’s ImprimisRx division, in addition to his current role as Chief Commercial Officer of the Company.
On November 3, 2023, R. Lawrence Van Horn informed the Board of Directors (the “Board”) of Harrow, Inc. (the “Company”) that he is resigning as a member of the Company’s Board, with such resignation to be effective immediately.
the Board appointed Mr. Perry J. Sternberg and Dr. Marty Makary to fill the vacancies created by Dr. Kammer’s resignation and the expansion of the size of the Board.
On March 31, 2022, Dr. Robert J. Kammer informed the Board of Directors (the “Board”) of Harrow Health, Inc. (the “Company”) that he is resigning as a member of the Company’s Board, with such resignation to be effective immediately.
the Board appointed Mr. Perry J. Sternberg and Dr. Marty Makary to fill the vacancies created by Dr. Kammer’s resignation and the expansion of the size of the Board.
Max materiality 0.85 · Median 0.65 · Most common event earnings